In biopharmaceutical analysis, undesired secondary analyte/surface interactions have hindered performance in HPLC. Analytes that contain electron rich functional groups, such as phosphate and carboxylate groups, are susceptible to absorb onto surfaces along the stainless-steel flow path causing reduced resolution and recovery. To overcome these challenges, hardware surfaces were modified with a chemically resistant hybrid organic/inorganic barrier and used in the construction of a bio-inert HPLC system. In this study, the bio-inert HPLC platform was evaluated by analysing several novel and traditional biotherapeutics and comparing it to legacy HPLC instruments.
Established methods that were previously analysed on legacy HPLC platforms and columns were scaled and transferred to the bio-inert HPLC platform. Ion-pairing reversed phase chromatography, size exclusion chromatography and reversed phase chromatography were used as the prevailing techniques for analysing biotherapeutics on both systems. This poster will demonstrate that the bio-inert HPLC platform can be broadly deployed to analyse new modalities and traditional biotherapeutics for routine analysis during manufacturing. We demonstrate that improved resolution and recovery can be achieved when compared to legacy HPLC systems.
Title | Format | File Size |
---|---|---|
Download PDF | 1116.32kB |